Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2021
Chinook Therapeutics (Nasdaq: KDNY) announced its participation in a virtual fireside chat at the William Blair Biotech Focus Conference on July 15, 2021, at 12:00 pm ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chinook Therapeutics (Nasdaq: KDNY) announced its participation in a virtual fireside chat at the William Blair Biotech Focus Conference on July 15, 2021, at 12:00 pm ET. Interested investors can access the live webcast and an archived recording on Chinook's website, available for 30 days. Chinook is focused on developing precision medicines for kidney diseases, with its lead program, atrasentan, in phase 3 trials for IgA nephropathy. The company is also advancing BION-1301 and CHK-336 for various kidney disorders, utilizing innovative research approaches.
Details
News Market Reaction – KDNY
The recorded move for KDNY in the trading session of this news was -1.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 12:00 pm ET.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 30 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
Contact:
Noopur Liffick
Vice President, Investor Relations & Corporate Communications
investors@chinooktx.com
media@chinooktx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.